Attached files
| file | filename |
|---|---|
| EX-10.19 - SETTLEMENT AGREEMENT - GT Biopharma, Inc. | gtbp_ex1019.htm |
| EX-10.20 - FORM OF SETTLEMENT NOTE - GT Biopharma, Inc. | gtbp_ex1020.htm |
| EX-10.22 - BOARD SERVICE AGREEMENT - GT Biopharma, Inc. | gtbp_ex1022.htm |
| EX-10.23 - BOARD SERVICE AGREEMENT - GT Biopharma, Inc. | gtbp_ex1023.htm |
| EX-10.24 - CONSULTANT AGREEMENT - GT Biopharma, Inc. | gtbp_ex1024.htm |
| EX-31.1 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - GT Biopharma, Inc. | gtbp_ex311.htm |
| 10-Q - QUARTERLY REPORT - GT Biopharma, Inc. | gtbp_10q.htm |
| EX-32.1 - CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE - GT Biopharma, Inc. | gtbp_ex321.htm |
Exhibit 10.21
November
11, 2020
Anthony
Cataldo
GT
Biopharma Inc.
9350
Wilshire Blvd., Suite 203
Beverly
Hills, CA 990212
Mr.
Cataldo:
This
letter is my notice of resignation as the Chief Financial Officer
and Director of GT Biopharma, Inc. effective
immediately.
Sincerely,
/s/
Steven Weldon
Steven
Weldon, MBA, CPA